Aptamer Group PLC Wastewater monitoring system installed in UK

TIDMAPTA

Aptamer Group PLC

28 March 2022

28 March 2022

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Optimer(R) -enabled wastewater monitoring system installed in UK networks

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(R) binders to enable innovation in the life sciences industry, notes the announcement today by DeepVerge plc (AIM:DVRG) that Optimer-enabled Microtox(R) PD systems for the detection of pathogens in wastewater have been installed at six sites across the UK as part of the Environmental Monitoring for Health Protection (EMHP) programme, with further installations expected in the UK over the next few months as part of the programme.

MicrotoxPD from DeepVerge offers real-time detection and monitoring of pathogens in wastewater and drinking water. This system relies on specific Optimer binders to pathogen targets of interest, coated on sensing chips within the units, to detect and monitor SARS-CoV-2 in wastewater. The SARS-CoV-2 Optimer binders were developed using the Company's proprietary discovery and development platform, with scalable manufacture to support the increased demand for sensors as more MicrotoxPD systems are deployed. Aptamer Group was selected as the preferred affinity ligand supplier for MicrotoxPD following performance evaluation of the SARS-CoV-2 Optimers in parallel with ligands from different suppliers.

An agreed extension of this partnership will see further Optimer binders developed for Influenza A, Influenza B, Polio and Pepper Mild Mottle Virus in wastewater and E.coli in drinking water to further expand the detection capabilities of the MicrotoxPD system.

The EMHP programme for wastewater monitoring is led by the Joint Biosecurity Centre (which forms part of NHS Test & Trace), DEFRA, academics and water companies. Data received from the MircotoxPD units under the programme will allow public health bodies to offer targeted containment in response to developing disease outbreaks, and identification of the SARS-CoV-2 variants of concern, each of which Aptamer's SARS-CoV-2 binder is able to detect.

Arron Tolley, Chief Executive Officer of Aptamer Group, commented: "We are really pleased to see the deployment of multiple Optimer-enabled MicrotoxPD units under the Environmental Monitoring for Health Protection programme. This will allow remote, real-time monitoring of water pathogens, particularly SARS-CoV-2, for the country to prepare for the next winter period. This Optimer-based detection offers increased national and international water safety through routine installations and monitoring, and we look forward to supporting our partners at DeepVerge through the supply of highly specific Optimer binders that enable specific and sensitive pathogen detection on their platform."

- ENDS -

For further information, please contact:

Aptamer Group plc

Dr Arron Tolley - CEO /

   Eleanor Brown (formerly Courtman-Stock) - CFO                       [phone] 

Consilium Strategic Communications

   Matthew Neal / Sukaina Virji / Lucy Featherstone                      [phone] 

[e-mail]

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary Optimer(R) platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUBOWRUKUOUAR

(END) Dow Jones Newswires

March 28, 2022 02:01 ET (06:01 GMT)